Sanofi un­der for­mal in­ves­ti­ga­tion for De­pakine al­le­ga­tions; Beam li­cens­es CAR-T tech from Ox­ford Bio­med­ica

Sanofi is fac­ing a for­mal in­ves­ti­ga­tion on manslaugh­ter charges, due to ac­cu­sa­tions that its epilep­sy drug De­pakine caused birth mal­func­tions and slow neu­ro­log­i­cal de­vel­op­ment when …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER